Skip to main content
Normal View

Rare Diseases Strategy

Dáil Éireann Debate, Tuesday - 14 July 2020

Tuesday, 14 July 2020

Questions (1288)

John Lahart

Question:

1288. Deputy John Lahart asked the Minister for Health when the proposed new national plan for rare diseases will be completed; if a consultation process will be run to allow input into this plan; and if he will make a statement on the matter. [15930/20]

View answer

Written answers

A National Rare Disease Plan for Ireland (2014 – 2018) was launched by the Minister for Health in July 2014. This is a generic policy framework for rare diseases. The scope of the plan is broad given that there are approximately 8,000 rare diseases affecting millions of EU citizens; and consequently, there can be a dearth of expertise and knowledge about some rare diseases, simply because they are so rare.

Many of the major recommendations of the plan have already been implemented including the establishment of a National Clinical Programme for Rare Diseases and a Rare Disease Office. Building on this progress to date, themes for inclusion in a roadmap for the coming period have been agreed with the Rare Disease Task Force, which comprises the main rare disease advocacy groups; Rare Disease Ireland, the Medical Research Charities Group (MRCP), and the Irish Platform for Patent Organisations, Science and Industry (IPPPOSI). The Rare Disease Plan is now firmly embedded in the work of the HSE Clinical Programme for Rare Diseases and the Rare Disease Office. This programme is now under the governance of the Office of the Chief Clinical Officer.

Meetings to ensure that the input and the voice of the patient is represented in the continuing work ongoing in relation to Rare Diseases take place at regular intervals with the Rare Disease Task Force, the HSE National Clinical Programme for Rare Diseases and the Rare Disease Office.

In addition, a number of key themes have been identified for future progress, including: Patient Awareness; European Reference Networks; Research & Registries; Access to Services; Access to Medicines; Diagnosis; Education & Training and Legislation & Policy.

Top
Share